SCHEMBL322265

SCHEMBL322265

FC(F)(F)C1CC[CH]CC1

nearest known ligand 0.30

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.30
NOS1 P29475 1/20 0.30
NOS2 P35228 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL863460 0.89
SCHEMBL2542443 0.87
SCHEMBL385788 0.85
SCHEMBL2540251 0.82
SCHEMBL13430636 0.81 NOS3 (0.30) NOS3NOS1NOS2
SCHEMBL11021725 0.77
SCHEMBL6180544 0.76
SCHEMBL18060 0.75
SCHEMBL1035408 0.75 NOS3 (0.36) NOS3NOS1NOS2
SCHEMBL588682 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115611856-B Piperidine derivative and pharmaceutical composition, preparation method and application thereof 宜昌人福药业有限责任公司 2024-07-05 CN claimed
CN-117881675-A 2, 4-dihydro-3H-1, 2, 4-triazol-3-one P2X7 antagonists 布雷耶疗法有限公司 2024-04-12 CN claimed
EP-4345096-A1 PIPERIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF Yichang Humanwell Pharmaceutical Co., Ltd. (CN) 2024-04-03 EP claimed
CN-110770214-B Heterocyclic P2X7 antagonists 布雷耶疗法有限公司 2024-03-29 CN claimed
CN-117642389-A Piperidine derivative and pharmaceutical composition, preparation method and application thereof 宜昌人福药业有限责任公司 2024-03-01 CN claimed
CN-117642402-A Spiropiperidine ring derivative and pharmaceutical composition, preparation method and application thereof 宜昌人福药业有限责任公司 2024-03-01 CN claimed
CN-117062815-A VMAT2 inhibitors and methods of use 纽罗克里生物科学有限公司 2023-11-14 CN claimed
US-20230278958-A1 TRICYCLIC HETEROCYCLES MERCK PATENT GMBH (DE) 2023-09-07 US claimed
US-20230174538-A1 Tricyclic heterocycles MERCK PATENT GMBH (DE) 2023-06-08 US claimed
EP-4185564-A1 TRICYCLIC HETEROCYCLES Merck Patent GmbH (DE) 2023-05-31 EP claimed
US-20010018446-A1 Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity G.D. SEARLE & CO. (US) 2001-08-30 US claimed
EP-1115694-A1 SUBSTITUTED N-ALIPHATIC-N-AROMATIC (TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY Monsanto Company (US) 2001-07-18 EP claimed
WO-2000018723-A1 SUBSTITUTED N-ALIPHATIC-N-AROMATIC TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY MONSANTO COMPANY (US) 2000-04-06 WO claimed
WO-2000012082-A1 FORMAMIDE COMPOUNDS AS THERAPEUTIC AGENTS GLAXO GROUP LIMITED (GB) 2000-03-09 WO claimed
WO-1994027972-A1 SUBSTITUTED PYRAZOLINES HAVING INSECTICIDAL AND ACARICIDAL ACTIVITY SCHERING AKTIENGESELLSCHAFT (DE) 1994-12-08 WO claimed
CN-1085549-A Cyanophenyl-pyrazolines SCHERING AG (DE) 1994-04-20 CN claimed
WO-1994007864-A1 CYANOPHENYLPYRAZOLINES AS PESTICIDES SCHERING AKTIENGESELLSCHAFT (DE) 1994-04-14 WO claimed
US-4968676-A PLANTS, SOILS, SEEDS BASF AKTIENGESELLSCHAFT (DE) 1990-11-06 US claimed
US-4897425-A Fungicidal cyclohexylamines BASF AKTIENGESELLSCHAFT (DE) 1990-01-30 US claimed
EP-0301376-A1 Rubber vulcanisation process using a vulcanisation system based on 2-nitrophenyl sulphenamides, 2-nitrophenyl sulphenamides, and their preparation BAYER AG (DE) 1989-02-01 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278958-A1 TRICYCLIC HETEROCYCLES YAP1, TERF2IP, TEAD1 NOS3 3864/4885NOS1 3802/4885NOS2 3931/4885
US-20010018446-A1 Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity CETP, DBI, MTTP NOS3 1775/4885NOS1 1573/4885NOS2 2404/4885
US-20230174538-A1 Tricyclic heterocycles YAP1, TEAD1, TERF2IP NOS3 3974/4885NOS1 3856/4885NOS2 3951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.